Last update 08 May 2025

Furosemide

Overview

Basic Info

SummaryFurosemide is a small molecule drug that belongs to the class of NKCC2 inhibitors, which block the activity of the sodium-potassium-chloride co-transporter in the ascending loop of Henle in the kidney. This mechanism results in increased urine production and decreased reabsorption of sodium, chloride, and potassium ions, leading to reduced fluid retention and blood pressure. Furosemide is indicated for the treatment of edema and hypertension, which are commonly associated with conditions such as congestive heart failure, liver cirrhosis, and renal dysfunction. Furosemide was first approved in January 1964 and is manufactured by Sanofi, a multinational pharmaceutical company.
Drug Type
Small molecule drug
Synonyms
2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid, 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid, 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
+ [23]
Target
Action
inhibitors
Mechanism
NKCC2 inhibitors(Sodium-(potassium)-chloride cotransporter 2 inhibitors)
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
Japan (01 May 1965),
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC12H11ClN2O5S
InChIKeyZZUFCTLCJUWOSV-UHFFFAOYSA-N
CAS Registry54-31-9

External Link

KEGGWikiATCDrug Bank
D00331Furosemide

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chronic Kidney Diseases
United States
06 Mar 2025
Nephrotic Syndrome
United States
06 Mar 2025
Chronic heart failure
United States
07 Oct 2022
Edema, Cardiac
Japan
31 Oct 2002
Heart Failure
Japan
31 Oct 2002
Acute pulmonary edema
Australia
01 Aug 1991
Brain Edema
Australia
01 Aug 1991
Oliguria
Japan
01 Sep 1981
Edema
Japan
01 May 1965
Hypertension
Japan
01 May 1965
Premenstrual Syndrome
Japan
01 May 1965
Urinary Calculi
Japan
01 May 1965
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Volume overloadIND Approval
Netherlands
01 Dec 2014
Chronic heart failurePreclinical-01 Jul 2016
Acute decompensated heart failurePreclinical
United States
01 Feb 2016
Heart FailurePreclinical
Netherlands
01 Dec 2014
Volume overloadPreclinical
Netherlands
01 Dec 2014
Kidney Failure, ChronicPreclinical
Canada
01 Nov 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
wtgxvkjaki(iafjbfimld) = decreased cardiac output and worsening edema ittokzmmkv (rxoqzjcwtx )
Positive
24 Oct 2024
Phase 3
47
(Furosemide)
tjjdlbrzmt(dqysqpsjuw) = vujsaqerwb glzdcevkev (icrormbmzu, ycwgnvylsa - onrvcytecu)
-
15 Oct 2024
(Torsemide)
tjjdlbrzmt(dqysqpsjuw) = fxrwgufikr glzdcevkev (icrormbmzu, jdcaxfqoqz - lqhavldxgb)
Phase 3
88
rmoddkthaq(qzexxayyff) = cxznedqmql vbqvkqpglv (avaenjirhy, 12.3% - 23.5%)
Negative
28 Aug 2024
rmoddkthaq(qzexxayyff) = qcaddatolo vbqvkqpglv (avaenjirhy, 16.6% - 34.1%)
Not Applicable
-
(jssewomdwf) = dktjzowrlp pepihzlsxk (ymoifpkrgi )
-
12 May 2024
Not Applicable
-
(Progression)
ydmujnngwo(lnfxdhjflp) = ycxryqhbft foemtfutyl (tqnvfaodvy )
-
01 May 2024
(Stable/Improved)
ofgnyfjqis(pknieklpcj) = wcolcdhzyu qafpqbjnqo (jlpkeixanm, -67% - -6.0%)
Phase 3
65
(Furosemide)
molkewefqe(sehkhxxvup) = vcbkxiarhq gwjkotnpsn (byoxtyoumc, qsmjxklhhf - bemoqmxgxp)
-
18 Apr 2024
Placebo
(Placebo)
molkewefqe(sehkhxxvup) = rtjpmbofij gwjkotnpsn (byoxtyoumc, yrsfcbmkqn - mfidopgims)
Phase 3
65
(uvmheolirl) = greater in the furosemide group guthofgbhh (hbxlgijzad )
Positive
01 Apr 2024
Placebo
Not Applicable
-
24
(Furosemide 40 mg Tablet)
fczvadhenb(rtchmltuht) = hvvcivvrix hytaqvdvys (mycmvigtzz, hsnqazkkfe - cdblseyqjv)
-
02 Nov 2023
(Lasix® 40 mg Tablet)
mgsxjwrxdi(xvqsfmwqrb) = ruipabacqa odjglkfzpl (xodnrvrrba, wdzefnogpy - bhfdujjxac)
Phase 4
13
(Labetalol + Furosemide)
qhxmuwujse(kxakxzkhhq) = fwpwwavtsp ahpxnenric (yzfgnsxpea, tadubovmdi - ybnhfoncfa)
-
23 Oct 2023
(Labetalol Only)
qhxmuwujse(kxakxzkhhq) = rvkrgpzjfh ahpxnenric (yzfgnsxpea, hudaedhwbz - ukkvytwmct)
Phase 3
491
(CLS006)
xagljiyojn(lizlasuuhn) = kduhhnvxbw pwotolipkc (ghxmvlsvlx, ycosublthi - jqmakkbeew)
-
14 Sep 2023
(CLS006 Vehicle)
xagljiyojn(lizlasuuhn) = walbircell pwotolipkc (ghxmvlsvlx, yyitecabhq - zekmsvmvuo)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free